Spyre Therapeutics Reports First Dosing of Participants in Phase 1 Trials for New Extended Half-Life Anti-TL1A Antibodies.

The U.S. FDA has given the green light to Biocon Biologics' biosimilar YESINTEK™, Bmab 1200, which is comparable to J&J's Stelara® (Ustekinumab).

In modern gene therapy, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are key nucleic acid drugs that offer new treatment options for genetic and complex diseases.

Alector reveals findings from the AL002 INVOKE-2 Phase 2 study on early Alzheimer’s disease and shares company updates.

the siRNA therapeutics market is projected to grow substantially from $12.7 billion in 2023 to $39.2 billion by 2029.

Tenaya Therapeutics has administered the first dose to a patient in the Phase 1b clinical study of TN-401, part of the RIDGE™-1 trial, aimed at treating ARRVC linked to PKP2.

Novartis' Kisqali® has secured approval from the European Commission for use in a wide range of patients with HR+/HER2- early breast cancer who are at high risk of recurrence.

Hanmi Pharmaceutical and Beijing Hanmi are advancing clinical trials for BH3120, a co-developed next-gen cancer immunotherapy.

Biohaven Offers Update on Taldefgrobep Alfa Development for Spinal Muscular Atrophy and Obesity.

GC Biopharma and Novel Pharma have started a global Phase I clinical trial for treating MPS IIIA, with the first patient now dosed.

Amgen reports significant weight loss with maritide in individuals with obesity or excess weight after 52 weeks in a phase 2 trial.

PTC Therapeutics' Phase 2 ALS Trial Fails Main Objective.